Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy
Cancer Science · 2023-12 · 114 (12) · 4484-4498
DOI: 10.1111/cas.15964 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 20.09.2023. Verfasst von Qilin Huai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Hope Run Special Fund of Cancer Foundation of China, Chinese Academy of Medical Sciences Initiative for Innovative Medicine, National Key Research and Development Program of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Neoadjuvant immunotherapy has significantly changed the therapeutic approach for treating patients with surgically resectable non‐small cell lung cancer (NSCLC). Here, peripheral blood inflammation‐based biomarkers as well as previously less focused eosinophil fraction, modified Glasgow prognostic score (mGPS), and prognostic nutritional index (PNI) were systematically included to comprehensively analyze their potential in predicting neoadjuvant immunotherapy efficacy and prognosis. We enrolled 189 patients (94 in training and 95 in validation cohorts) with stage I–III B surgically resectable NSCLC treated with neoadjuvant immunotherapy from the National Cancer Center of China. Baseline and post‐treatment eosinophils fraction, neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), systemic immune‐inflammation index (SII), monocyte‐to‐lymphocyte ratio (MLR), PNI, mGPS, and their changes were calculated and analyzed for correlation with neoadjuvant immunotherapy efficacy and prognosis. In patients in the major pathological response (MPR) group, the post‐treatment eosinophil fraction was significantly high, and NLR, PLR, SII, and MLR were significantly lower compared to the non‐MPR group in both the training and validation cohorts. The receiver operating characteristic curve showed that post‐treatment, eosinophil fraction and SII and their changing were two of the most important factors. Univariate and multivariate logistic regression analyses showed that post‐treatment eosinophil fraction, SII, mGPS, and ΔSII could independently predict MPR in patients treated with neoadjuvant immunotherapy. Survival analysis showed a significant correlation between high post‐treatment NLR, PLR, SII, mGPS, and their changes in ΔNLR and ΔSII elevation with poor overall survival and event‐free survival of patients. Our results suggest that inflammatory biomarkers could predict the patient's response to neoadjuvant immunotherapy and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Key Laboratory of Minimally Invasive Therapy Research for Lung Cancer, Chinese Academy of Medical Sciences, Beijing, China.
ORCID-Profile: Bolun Zhou, Wei Guo
Förderung
- Beijing Hope Run Special Fund of Cancer Foundation of China
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Non-proft Central Research Institute Fund of Chinese Academy of Medical Sciences
- Special Research Fund for Central Universities, Peking Union Medical College
Zitieren
APA
Huai, Q., Luo, C., Song, P., Bie, F., Bai, G., Li, Y., Liu, Y., Chen, X., Zhou, B., Sun, X., Guo, W., & Gao, S. (2023). Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy. Cancer Science, 114(12), 4484-4498. https://doi.org/10.1111/cas.15964
Vancouver
Huai Q, Luo C, Song P, Bie F, Bai G, Li Y, et al. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy. Cancer Science. 2023;114(12):4484-4498. doi:10.1111/cas.15964
BibTeX
@article{Huai2023,
author = {Huai, Qilin and Luo, Chenyu and Song, Peng and Bie, Fenglong and Bai, Guangyu and Li, Yuan and Liu, Yang and Chen, Xiaowei and Zhou, Bolun and Sun, Xujie and Guo, Wei and Gao, Shugeng},
title = {Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy},
journal = {Cancer Science},
year = {2023},
volume = {114},
number = {12},
pages = {4484--4498},
doi = {10.1111/cas.15964}
}
EUVIMED